Related references
Note: Only part of the references are listed.Converging Goals of Treatment of Inflammatory Bowel Disease From Clinical Trials and Practice
Barrett G. Levesque et al.
GASTROENTEROLOGY (2015)
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
Niels Vande Casteele et al.
GUT (2015)
Association Between Thiopurine Use and Nonmelanoma Skin Cancers in Patients With Inflammatory Bowel Disease: A Meta-Analysis
Jonathan Ariyaratnam et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-alpha agents
Gionata Fiorino et al.
AUTOIMMUNITY REVIEWS (2014)
Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease
Brian G. Feagan et al.
GASTROENTEROLOGY (2014)
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
Remo Panaccione et al.
GASTROENTEROLOGY (2014)
Tailoring anti-TNF therapy in IBD: drug levels and disease activity
Shomron Ben-Horin et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2014)
Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2)
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Hepatosplenic γδ T-cell Lymphoma: An Overview
Koppany Visnyei et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Adverse Events of Tumor Necrosis Factor Inhibitors
Klaus Fellermann
DIGESTIVE DISEASES (2013)
Early Administration of Azathioprine vs Conventional Management of Crohn's Disease: A Randomized Controlled Trial
Jacques Cosnes et al.
GASTROENTEROLOGY (2013)
Early Azathioprine Therapy Is No More Effective Than Placebo for Newly Diagnosed Crohn's Disease
Julian Panes et al.
GASTROENTEROLOGY (2013)
Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature
Satveer K. Mahil et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2013)
Toll-like receptor signaling and regulation of intestinal immunity
Karishma Kamdar et al.
VIRULENCE (2013)
UEG Week 2013 Oral Presentations
United European Gastroenterology Journal (2013)
A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Ustekinumab Treatment of TNF Antagonist-Induced Paradoxical Psoriasis Flare in a Patient with Psoriatic Arthritis: Case Report and Review
Lluis Puig et al.
DERMATOLOGY (2012)
Nodular melanoma arising in a patient treated with anti-tumor necrosis factor alpha antagonists
Marta Carlesimo et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2012)
Lupus-Like Syndrome Attributable to Anti—Tumor Necrosis Factor α Therapy in 14 Patients During an 8-Year Period at Mayo Clinic
David A. Wetter et al.
MAYO CLINIC PROCEEDINGS (2012)
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Glucocorticosteroid Therapy in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Efficacy of Immunosuppressive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Khurram J. Khan et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Interleukin-23: A key cytokine in inflammatory diseases
Emilie Duvallet et al.
ANNALS OF MEDICINE (2011)
Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease
Laurent Peyrin-Biroulet et al.
GASTROENTEROLOGY (2011)
Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change
Ingrid Ordas et al.
GUT (2011)
TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists
Victoria L. Williams et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2011)
Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease
M. A. Smith et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Enhand secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn's disease
H.-C. REINECKER et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Severe Skin Lesions Cause Patients With Inflammatory Bowel Disease to Discontinue Anti-Tumor Necrosis Factor Therapy
Jean-Francois Rahier et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
Neurological adverse events associated with anti-tumor necrosis factor alpha treatment
Antonio G. Tristano
JOURNAL OF NEUROLOGY (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Optimising use of thiopurines in inflammatory bowel disease
Lawrence Sunder Raj et al.
FRONTLINE GASTROENTEROLOGY (2010)
Primary cutaneous melanoma: a complication of infliximab treatment?
I. Khan et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2009)
Risk of Lymphoma Associated With Combination Anti-Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis
Corey A. Siegel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study
H. Fidder et al.
GUT (2009)
Dermatological complications and safety of anti-TNF treatments
Joseph F. Kerbleski et al.
GUT (2009)
MECHANISMS OF DISEASE Inflammatory Bowel Disease
Clara Abraham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Common Skin Cancers and Their Precursors
Alisha Arora et al.
SURGICAL CLINICS OF NORTH AMERICA (2009)
A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
William J. Sandborn et al.
GASTROENTEROLOGY (2008)
Risk factors for opportunistic infections in patients with inflammatory bowel disease
Murat Toruner et al.
GASTROENTEROLOGY (2008)
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease:: an open randomised trial
Geert D'Haens et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
Drug-induced lupus due to anti-tumor necrosis factor α agents
Michelle F. Costa et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2008)
Lymphoma risk in inflammatory bowel disease: Is it the disease or its treatment?
Jennifer L. Jones et al.
INFLAMMATORY BOWEL DISEASES (2007)
Unravelling the pathogenesis of inflammatory bowel disease
R. J. Xavier et al.
NATURE (2007)
Autoimmune diseases induced by TNF-targeted therapies -: Analysis of 233 cases
Manuel Ramos-Casals et al.
MEDICINE (2007)
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease
Ann Corken Mackey et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2007)
NK-cell-associated receptor expression in hepatosplenic T-cell lymphoma, insights into pathogenesis
WG Morice et al.
LEUKEMIA (2006)
Paradoxical roles of the immune system during cancer development
KE de Visser et al.
NATURE REVIEWS CANCER (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Brief report - Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
G Van Assche et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Medical progress - Psoriasis
MP Schon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Risk of haematopoietic cancer in patients with inflammatory bowel disease
J Askling et al.
GUT (2005)
Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study
M Flendrie et al.
ARTHRITIS RESEARCH & THERAPY (2005)
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey
M De Bandt et al.
ARTHRITIS RESEARCH & THERAPY (2005)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark
T Jess et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Long-term Risk of Cancer in Ulcerative Colitis: A Population-Based Cohort Study From Copenhagen County
Karen V. Winther et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome:: report on a series of 21 patients
K Belhadj et al.
BLOOD (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Inflammatory bowel disease is not associated with an increased risk of lymphoma
JD Lewis et al.
GASTROENTEROLOGY (2001)
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease
BG Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Hodgkin's disease risk is increased in patients with ulcerative colitis
D Palli et al.
GASTROENTEROLOGY (2000)
Molecular mechanisms of glucocorticosteroid actions
IM Adcock
PULMONARY PHARMACOLOGY & THERAPEUTICS (2000)
Share Paper
